NewcelX Reports 2025 Financial Results and Provides Update on NCEL-101 for Type 1 Diabetes

NewcelX Ltd. (Nasdaq: NCEL) reported financial results for the full year ended December 31, 2025, and provided a corporate update focused on its regenerative medicine pipeline. The company reported a net loss of $8.3 million for 2025, significantly impacted by $5.7 million in non-cash finance expenses related to convertible instruments. Cash and cash equivalents stood at $2.2 million at year-end. A key highlight is the accelerated development of NCEL-101, a stem-cell-derived islet therapy for Type 1 Diabetes, developed in collaboration with Eledon Pharmaceuticals. The company is currently focused on IND-enabling activities, including manufacturing preparations with CDMO Pluri Inc. and regulatory planning. Beyond its flagship diabetes program, NewcelX continues to advance AstroRx for ALS and DOXA for narcolepsy. In April 2026, the company strengthened its balance sheet by closing a $1.35 million private placement with potential total proceeds of $3.4 million upon warrant exercise, while maintaining access to a $25 million Equity Line of Credit. The company expects 2026 to be a year of accelerated execution toward IND milestones.